Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Categories: @vaccine-makers   

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Website: pfizer.com



Growth: Good revenue growth rate 24.7%, there is acceleration compared to average historical growth rates -0.3%. The revenue growth dynamics is unstable Site traffic for the last 3 months showed a change of +5.8%

Profitability: LTM EBITDA margin is positive, +23.2%. On average the margin is improving unsteadily. In the last quarter the company beat the estimated EPS, +25.5%. The company was ahead of estimated EPS in 100% of quarters (showing a gain of +$0.23 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 6.3%. Free cash flow yield 0.0% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 7.6% higher than minimum and 51.6% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 3x by EV / Sales multiple , the company can be 9.1% overvalued

Insiders: For the last 3 months insiders bought company shares on $0.5 mln (0.000% of cap.)

Key Financials (Download financials)

Ticker: PFE
Share price, USD:  (+0.1%)26.6784
year average price 27.60  


year start price 26.89 2024-02-27

max close price 31.39 2024-07-30

min close price 24.80 2024-11-15

current price 26.68 2025-02-25
Common stocks: 5 615 000 000

Dividend Yield:  6.3%
EV / LTM EBITDA: 14.1x
EV / EBITDA annualized: 24.8x
EV / Sales: 3.3x
Margin (EBITDA LTM / Revenue): 23.2%
Fundamental value created in LTM:
Market Cap ($m): 149 799
Net Debt ($m): 58 021
EV (Enterprise Value): 207 820
Price to Book: 1.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-02-25zacks.com

Summit Incurs In-Line Q4 Loss, Inks Collaboration Deal With Pfizer

2025-02-24prnewswire.com

Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs

2025-02-24reuters.com

Pfizer names former FDA director Patrizia Cavazzoni as chief medical officer

2025-02-24seekingalpha.com

Pfizer: What The Summit Therapeutics Deal Brings

2025-02-24globenewswire.com

INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (NYSE: PFE)

2025-02-22seekingalpha.com

Pfizer: No More Growth - Still A Worthy Dividend Buy

2025-02-21fool.com

2 No-Brainer Healthcare Stocks to Buy With $500 Right Now

2025-02-20reuters.com

Pfizer says it will end global development of gene therapy Beqvez, Nikkei reports

2025-02-19seekingalpha.com

Why Pfizer's Stock Price Isn't Reflecting Its True Value

2025-02-19seekingalpha.com

Pfizer Stock's Upside Got Bigger
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-29 2024-06-30 2024-03-31 2023-12-31 2023-10-01 2023-07-02 2023-04-02 2022-12-31 2022-10-02
symbol PFE PFE PFE PFE PFE PFE PFE PFE PFE
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 78 003 78 003 78 003 78 003 78 003 78 003 78 003 78 003 78 003
fillingDate 2024-11-04 2024-08-05 2024-05-08 2024-02-22 2023-11-08 2023-08-09 2023-05-10 2023-02-23 2022-11-09
acceptedDate 2024-11-04 16:06:08 2024-08-05 15:54:43 2024-05-08 15:56:17 2024-02-22 13:17:37 2023-11-08 16:00:02 2023-08-09 16:11:52 2023-05-10 15:53:31 2023-02-23 14:12:53 2022-11-09 16:05:15
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 17 702M 13 283M 14 879M 14 249M 13 232M 12 734M 18 282M 24 290M 22 638M
costOfRevenue 6 575M 5 040M 4 381M 8 592M 10 603M 3 237M 4 886M 9 648M 6 063M
grossProfit 11 127M 8 243M 10 498M 5 657M 2 629M 9 497M 13 396M 14 642M 16 575M
grossProfitRatio 0.629 0.621 0.706 0.397 0.199 0.746 0.733 0.603 0.732
researchAndDevelopmentExpenses 2 598M 2 676M 2 480M 2 773M 2 682M 2 648M 2 505M 3 615M 2 696M
generalAndAdministrativeExpenses 0 0 0 777M 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 3 700M 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 3 244M 3 688M 3 459M 4 477M 3 212M 3 497M 3 418M 4 644M 3 391M
otherExpenses 0 230M 361M 1 030M 574M 385M 1 103M 1 130M 822M
operatingExpenses 5 842M 6 364M 5 939M 7 250M 5 894M 7 329M 7 026M 9 389M 6 909M
costAndExpenses 12 417M 11 404M 10 320M 15 842M 16 497M 10 566M 11 912M 19 037M 12 972M
interestIncome 116M 130M 129M 609M 523M 316M 177M 137M 70M
interestExpense 783M 778M 790M 688M 695M 508M 318M 313M 311M
depreciationAndAmortization 1 755M 1 731M 1 736M 43 812 1 560M 1 184M 1 103M 1 130M 822M
ebitda 7 253M 2 405M 6 295M 77M -1 705M 4 210M 8 396M 7 562M 11 249M
ebitdaratio 0.41 0.272 0.423 0.005 -0.129 0.331 0.459 0.311 0.497
operatingIncome 5 284M 1 879M 4 559M -1 593M -3 265M 3 026M 7 293M 6 432M 10 427M
operatingIncomeRatio 0.298 0.141 0.306 -0.112 -0.247 0.238 0.399 0.265 0.461
totalOtherIncomeExpensesNet -569M -1 982M -1 138M -2 536M -87M 292M -1 023M -1 201M -1 426M
incomeBeforeTax 4 715M -103M 3 421M -4 129M -3 352M 2 269M 6 270M 5 231M 9 001M
incomeBeforeTaxRatio 0.266 -0.008 0.23 -0.29 -0.253 0.178 0.343 0.215 0.398
incomeTaxExpense 234M -134M 293M -794M -964M -71M 715M 230M 356M
netIncome 4 465M 24M 3 115M -3 344M -2 394M 2 327M 5 543M 4 995M 8 608M
netIncomeRatio 0.252 0.002 0.209 -0.235 -0.181 0.183 0.303 0.206 0.38
eps 0.79 0.004 0.55 -0.59 -0.42 0.41 0.98 0.89 1.54
epsdiluted 0.78 0.004 0.55 -0.59 -0.42 0.41 0.97 0.87 1.51
weightedAverageShsOut 5 667M 5 666M 5 657M 5 647M 5 646M 5 646M 5 634M 5 615M 5 607M
weightedAverageShsOutDil 5 705M 5 696M 5 697M 5 647M 5 646M 5 713M 5 727M 5 743M 5 718M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-29 2024-06-30 2024-03-31 2023-12-31 2023-10-01 2023-07-02 2023-04-02 2022-12-31 2022-10-02
symbol PFE PFE PFE PFE PFE PFE PFE PFE PFE
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 78 003 78 003 78 003 78 003 78 003 78 003 78 003 78 003 78 003
fillingDate 2024-11-04 2024-08-05 2024-05-08 2024-02-22 2023-11-08 2023-08-09 2023-05-10 2023-02-23 2022-11-09
acceptedDate 2024-11-04 16:06:08 2024-08-05 15:54:43 2024-05-08 15:56:17 2024-02-22 13:17:37 2023-11-08 16:00:02 2023-08-09 16:11:52 2023-05-10 15:53:31 2023-02-23 14:12:53 2022-11-09 16:05:15
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 1 092M 1 052M 719M 2 853M 3 148M 2 632M 2 166M 416M 1 298M
shortTermInvestments 8 860M 6 048M 11 209M 9 837M 41 033M 42 153M 17 806M 22 316M 34 825M
cashAndShortTermInvestments 9 952M 7 100M 11 928M 12 690M 44 181M 44 785M 19 972M 22 732M 36 123M
netReceivables 14 451M 11 393M 10 989M 11 177M 11 086M 13 425M 15 445M 14 529M 18 620M
inventory 11 721M 11 448M 10 892M 10 189M 10 204M 10 310M 9 541M 8 981M 9 513M
otherCurrentAssets 7 099M 7 885M 8 606M 9 277M 8 541M 4 827M 5 120M 5 017M 6 147M
totalCurrentAssets 43 223M 37 825M 42 415M 43 333M 74 012M 73 347M 50 078M 51 259M 70 403M
propertyPlantEquipmentNet 18 541M 18 957M 18 803M 21 864M 17 862M 17 488M 17 052M 16 274M 15 441M
goodwill 68 570M 68 445M 69 297M 67 783M 51 527M 51 572M 51 476M 51 375M 49 441M
intangibleAssets 59 986M 61 240M 62 828M 64 900M 40 224M 41 407M 42 001M 43 370M 28 150M
goodwillAndIntangibleAssets 128 556M 129 685M 132 125M 132 683M 91 751M 92 979M 93 477M 94 745M 77 591M
longTermInvestments 10 762M 11 522M 12 003M 15 770M 14 653M 15 066M 14 743M 15 069M 13 888M
taxAssets 7 909M 7 867M 4 942M 3 706M 8 350M 8 261M 7 302M 6 693M 7 136M
otherNonCurrentAssets 10 485M 10 337M 10 807M 9 145M 8 393M 13 028M 12 965M 13 163M 10 890M
totalNonCurrentAssets 176 253M 178 368M 178 680M 183 168M 141 009M 146 822M 145 539M 145 944M 124 946M
otherAssets 0 0 0 0 0 -1 000 000 0 3M 0
totalAssets 219 476M 216 193M 221 095M 226 501M 215 021M 220 168M 195 617M 197 206M 195 349M
accountPayables 5 314M 5 106M 5 591M 6 710M 5 338M 6 081M 6 123M 6 809M 6 267M
shortTermDebt 9 699M 9 378M 8 232M 10 877M 2 548M 3 985M 4 189M 2 945M 4 024M
taxPayables 2 877M 2 884M 3 192M 2 349M 1 898M 2 928M 1 969M 1 587M 3 071M
deferredRevenue 2 020M 2 528M 2 502M 2 700M 2 204M 1 286M 1 750M 2 520M 6 191M
otherCurrentLiabilities 23 301M 21 357M 24 172M 27 507M 21 046M 23 295M 24 500M 29 864M 27 832M
totalCurrentLiabilities 43 211M 43 819M 40 497M 47 794M 31 136M 34 647M 36 562M 42 138M 44 314M
longTermDebt 58 002M 57 506M 61 307M 61 538M 61 048M 61 356M 30 738M 31 925M 31 653M
deferredRevenueNonCurrent 0 0 0 2 626M 0 10 236M 0 0 0
deferredTaxLiabilitiesNonCurrent 2 158M 2 227M 931M 640M 1 125M 1 232M 1 067M 1 023M 616M
otherNonCurrentLiabilities 23 547M 24 666M 25 801M 24 615M 24 507M 13 404M 26 014M 26 203M 41 663M
totalNonCurrentLiabilities 83 707M 84 400M 88 039M 89 419M 86 680M 86 228M 57 819M 59 151M 58 145M
otherLiabilities 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 -2 566M 0 2 626M 0 0 0 0 0
totalLiabilities 126 918M 128 219M 128 536M 137 213M 117 816M 120 875M 94 381M 101 289M 102 459M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 480M 480M 480M 478M 478M 478M 478M 476M 476M
retainedEarnings 121 059M 116 596M 121 318M 118 353M 126 411M 128 796M 131 102M 125 656M 122 967M
accumulatedOtherComprehensiveIncomeLoss -7 971M -7 816M -7 758M -7 961M -7 966M -8 102M -8 289M -8 304M -8 225M
othertotalStockholdersEquity -21 282M -21 560M -21 758M -21 856M -21 989M -22 153M -22 321M -22 167M -22 587M
totalStockholdersEquity 92 286M 87 700M 92 282M 89 014M 96 934M 99 019M 100 970M 95 661M 92 631M
totalEquity 92 558M 87 975M 92 558M 89 288M 97 204M 99 293M 101 236M 95 661M 92 631M
totalLiabilitiesAndStockholdersEquity 219 476M 216 194M 221 094M 226 501M 215 020M 220 168M 195 617M 197 206M 195 349M
minorityInterest 272M 275M 276M 274M 270M 274M 266M 256M 0
totalLiabilitiesAndTotalEquity 219 476M 216 194M 221 094M 226 501M 215 020M 220 168M 195 617M 197 206M 195 349M
totalInvestments 19 622M 17 570M 23 212M 25 607M 55 686M 53 575M 19 638M 37 385M 48 713M
totalDebt 66 617M 69 450M 69 539M 75 041M 63 596M 65 341M 34 927M 34 870M 35 677M
netDebt 65 525M 68 398M 68 820M 72 188M 60 448M 62 709M 32 761M 34 454M 34 379M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-29 2024-06-30 2024-03-31 2023-12-31 2023-10-01 2023-07-02 2023-04-02 2022-12-31 2022-10-02
symbol PFE PFE PFE PFE PFE PFE PFE PFE PFE
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 78 003 78 003 78 003 78 003 78 003 78 003 78 003 78 003 78 003
fillingDate 2024-11-04 2024-08-05 2024-05-08 2024-02-22 2023-11-08 2023-08-09 2023-05-10 2023-02-23 2022-11-09
acceptedDate 2024-11-04 16:06:08 2024-08-05 15:54:43 2024-05-08 15:56:17 2024-02-22 13:17:37 2023-11-08 16:00:02 2023-08-09 16:11:52 2023-05-10 15:53:31 2023-02-23 14:12:53 2022-11-09 16:05:15
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome 4 473M 24M 3 120M -3 344M -2 394M 2 340M 5 555M 5 001M 8 644M
depreciationAndAmortization 1 755M 1 731M 1 736M 1 670M 1 560M 1 573M 1 487M 1 519M 1 183M
deferredIncomeTax -482M -783M -441M -1 858M -113M -873M -598M -365M 62M
stockBasedCompensation 274M 206M 220M 121M 151M 148M 105M 364M 135M
changeInWorkingCapital 6 871M -3 535M -3 336M 8 450M -1 199M -3 916M -5 507M 3 149M -4 109M
accountsReceivables 0 0 0 347M 0 0 0 261M 0
inventory 0 0 0 -1 169M 0 0 0 592M 0
accountsPayables 0 0 0 822M 0 0 0 1 191M 0
otherWorkingCapital 6 871M -3 535M -3 336M 8 450M -1 199M 0 0 1 105M 0
otherNonCashItems -6 177M 4 243M 3 484M 201M 5 451M -480M 170M -1 086M 59M
netCashProvidedByOperatingActivities 6 714M -1 782M 1 091M 5 240M 3 456M -1 208M 1 212M 8 582M 5 974M
investmentsInPropertyPlantAndEquipment -651M -637M -704M -1 044M -810M -914M -1 139M -1 001M -841M
acquisitionsNet 0 0 3 491M -43 405M -2M -25M 0 -16 772M 0
purchasesOfInvestments -2 670M 657M -2 019M -874M -9 206M -25 599M -6 716M 3 425M -18 791M
salesMaturitiesOfInvestments 1 258M 4 599M 4 454M 34 312M 10 556M 1 577M 11 189M 9 929M 15 156M
otherInvestingActivites 6M -18M 1 000 000 15M 350M -524M -19M 9M 3 849M
netCashUsedForInvestingActivites -2 057M 4 600M 1 732M -10 996M 888M -25 485M 3 315M -4 410M -627M
debtRepayment -2 250M -16M -2 173M -7 775M -1 428M -1 000M -269M -1 911M -3 887M
commonStockIssued 0 0 0 0 0 0 0 0 0
commonStockRepurchased 0 0 0 0 0 0 0 2000 0
dividendsPaid -2 380M -2 380M -2 372M -2 315M -2 314M -2 315M -2 303M -2 245M -2 245M
otherFinancingActivites -6M -63M -386M 15 532M -37M 30 489M -199M -859M 371M
netCashUsedProvidedByFinancingActivities -4 636M -2 459M -4 931M 5 442M -3 779M 27 174M -2 771M -5 015M -5 761M
effectOfForexChangesOnCash 9M -18M -28M -1 000 000 -32M -5M -2M -26M -72M
netChangeInCash 100M 333M -2 134M -295M 516M 476M 1 754M -870M -486M
cashAtEndOfPeriod 1 152M 1 052M 719M 2 853M 3 148M 2 698M 2 222M 468M 1 338M
cashAtBeginningOfPeriod 1 052M 719M 2 853M 3 148M 2 632M 2 222M 468M 1 338M 1 824M
operatingCashFlow 6 714M -1 782M 1 091M 5 240M 3 456M -1 208M 1 212M 8 582M 5 974M
capitalExpenditure -651M -637M -704M -1 044M -810M -914M -1 139M -1 001M -841M
freeCashFlow 6 063M -2 419M 387M 4 196M 2 646M -2 122M 73M 7 581M 5 133M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

2024 q3
2024-10-29 ET (fiscal 2024 q3)
2024 q2
2024-07-30 ET (fiscal 2024 q2)
2024 q1
2024-05-01 ET (fiscal 2024 q1)
2023 q4
2024-01-30 ET (fiscal 2023 q4)
2023 q3
2023-10-31 ET (fiscal 2023 q3)
2023 q2
2023-08-01 ET (fiscal 2023 q2)
2023 q1
2023-05-02 ET (fiscal 2023 q1)
2022 q4
2023-01-31 ET (fiscal 2022 q4)
2022 q3
2022-11-01 ET (fiscal 2022 q3)
2022 q2
2022-07-28 ET (fiscal 2022 q2)
2022 q1
2022-05-03 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-10-29 10:45 ET
Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance
2024-10-15 10:45 ET
Tim Buckley Elected to Pfizer’s Board of Directors
2024-10-11 17:23 ET
U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors
2024-10-10 12:45 ET
Starboard Value Issues Letter to Pfizer’s Board of Directors
2024-10-10 10:51 ET
Pfizer’s TALZENNA® in Combination with XTANDI® Prolongs Overall Survival in Phase 3 TALAPRO-2 Trial
2024-10-09 20:30 ET
Pfizer Declares Fourth-Quarter 2024 Dividend
2024-10-08 20:45 ET
Pfizer to Showcase Scientific Advancements in Respiratory and Other Infectious Diseases at IDWeek 2024
2024-10-07 11:00 ET
ViiV Healthcare to triple annual supply of long-acting HIV PrEP for low- and middle-income countries
2024-09-25 21:00 ET
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets
2024-09-20 12:11 ET
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
2024-09-17 14:00 ET
Pfizer Invites Public to View and Listen to Webcast of October 29 Conference Call with Analysts
2024-09-14 12:45 ET
Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia
2024-09-14 08:15 ET
Pfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
2024-09-11 10:45 ET
Pfizer Highlights Diverse Oncology Portfolio and Combination Approaches at ESMO 2024
2024-08-28 14:00 ET
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
2024-08-27 10:45 ET
Pfizer Launches PfizerForAll™, a Digital Platform that Helps Simplify Access to Healthcare
2024-08-22 18:15 ET
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
2024-08-16 10:45 ET
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
2024-08-12 10:45 ET
Pfizer Announces Top-Line Results of ABRYSVO® for RSV in Immunocompromised Adults
2024-07-31 12:00 ET
Telescope Innovations and Pfizer Sign Master Collaborative Research Agreement
2024-07-30 10:45 ET
Pfizer Reports Strong Second-Quarter 2024 Results And Raises 2024 Guidance
2024-07-25 14:48 ET
European Commission Approves Pfizer’s DURVEQTIX® (fidanacogene elaparvovec), a One-Time Gene Therapy for Adults with Hemophilia B
2024-07-24 10:45 ET
Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate
2024-07-23 08:06 ET
ViiV Healthcare announces positive data demonstrating 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy for maintenance therapy of HIV-1
2024-07-11 10:45 ET
Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron
2024-07-09 10:45 ET
Pfizer to Launch Process to Identify a Successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development
2024-07-08 12:00 ET
CBIH: Unleashing the Potential of Cannabis for Tomorrow's Medicine
2024-07-01 10:45 ET
Cyrus Taraporevala Elected to Pfizer’s Board of Directors
2024-06-27 14:30 ET
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
2024-06-26 20:30 ET
Pfizer Declares Third-Quarter 2024 Dividend
2024-06-18 14:00 ET
Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts
2024-06-14 07:00 ET
ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma
2024-06-12 20:30 ET
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with Duchenne Muscular Dystrophy
2024-06-05 20:05 ET
Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608
2024-06-03 14:00 ET
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
2024-06-01 12:00 ET
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
2024-06-01 12:00 ET
Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL)
2024-05-31 12:00 ET
Pfizer’s LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression
2024-05-16 10:00 ET
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
2024-05-13 12:00 ET
Astellas Showcases Scientific Advancements Across its Oncology Portfolio at 2024 ASCO Annual Meeting
2024-05-06 10:45 ET
Pfizer Announces New Chief Strategy and Innovation Officer
2024-05-01 10:45 ET
Pfizer Reports First-Quarter 2024 Results
2024-04-29 22:40 ET
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
2024-04-29 22:40 ET
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
2024-04-29 10:45 ET
Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting
2024-04-26 10:45 ET
U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
2024-04-24 20:37 ET
Pfizer Declares Second-Quarter 2024 Dividend
2024-04-22 12:08 ET
European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options
2024-04-11 14:00 ET
Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25
2024-04-09 10:45 ET
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
2024-04-08 12:23 ET
ViiV Healthcare announces U.S. FDA approval of Dovato (dolutegravir/lamivudine) for adolescents living with HIV
2024-03-20 14:00 ET
Pfizer Invites Public to View and Listen to Webcast of May 1 Conference Call with Analysts
2024-03-13 08:00 ET
European Commission Approves Pfizer’s PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease
2024-03-12 10:45 ET
Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL)
2024-03-06 17:05 ET
ViiV Healthcare Announces Interim Data at CROI Indicating Superior Efficacy of Long-Acting Injectable HIV Treatment Cabenuva (Cabotegravir + Rilpivirine) Compared to Daily Oral Therapy in Individuals Living With HIV Who Have Adherence Challenges
2024-03-05 15:00 ET
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
2024-03-05 13:48 ET
ViiV Healthcare and The American Academy of HIV Medicine Announce Fellowship to Improve HIV Prevention in Key Communities
2024-03-04 18:50 ET
ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses
2024-02-29 22:40 ET
Pfizer Oncology Hosts Innovation Day, Highlighting Fully Integrated Organization, Robust Portfolio, and Strategic Priorities to Drive Long-Term Sustainable Growth
2024-02-29 13:00 ET
Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO® for RSV in Older Adults
2024-02-26 15:00 ET
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
2024-02-22 00:48 ET
Everest Medicines' Partner Pfizer Announces European Commission Approves VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis
2024-02-19 12:45 ET
European Commission Approves Pfizer’s VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis
2024-02-15 15:00 ET
Pfizer Invites Public to Register for Webcast of Pfizer Oncology Innovation Day
2024-02-05 16:00 ET
ViiV Healthcare announces new packaging option now available in the U.S. for Dovato (dolutegravir/lamivudine)
2024-02-05 15:00 ET
Breaking Barriers in Cancer Care: The American Cancer Society and Pfizer Announce a $15 Million, Three-Year Initiative to Bridge the Gap in Cancer Care Disparities
2024-01-30 11:45 ET
Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance
2024-01-26 17:00 ET
European Medicines Agency Validates Type II Variation Application for PADCEV™ (enfortumab vedotin) with KEYTRUDA®(pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
2024-01-26 17:00 ET
European Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
2024-01-10 21:30 ET
Pfizer Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation
2024-01-09 11:45 ET
TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer
2024-01-09 11:45 ET
TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
2024-01-08 15:35 ET
European Commission Approves Pfizer’s TALZENNA® in Combination with XTANDI® for Adult Patients with Metastatic Castration-Resistant Prostate Cancer
2024-01-02 15:00 ET
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
2023-12-19 15:00 ET
Pfizer Invites Public to View and Listen to Webcast of January 30 Conference Call with Analysts
2023-12-15 22:00 ET
PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
2023-12-14 21:30 ET
Pfizer Declares First-Quarter 2024 Dividend
2023-12-13 11:45 ET
Pfizer Provides Full-Year 2024 Guidance
2023-12-11 21:30 ET
FDA and EMA Accept Marstacimab Regulatory Submissions for the Treatment of Hemophilia A and B
2023-12-10 00:00 ET
Marstacimab Phase 3 Data Presented at ASH 2023 Demonstrate Significant Bleed Reduction in Hemophilia A and B
2023-12-08 12:55 ET
European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma
2023-12-01 11:45 ET
Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity
2023-11-21 15:00 ET
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
2023-11-17 03:33 ET
Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting
2023-11-02 14:52 ET
Pfizer Highlights Scientific Advances from Growing Hematology Portfolio at American Society of Hematology Annual Meeting
2023-11-02 14:00 ET
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
2023-10-31 10:45 ET
Pfizer Reports Third-Quarter 2023 Results
2023-10-20 19:35 ET
FDA Approves PENBRAYA™, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents
2023-10-15 23:44 ET
Everest Medicines' Licensing Partner Pfizer Announces U.S. FDA Approves Etrasimod for Adults with Moderately to Severely Active Ulcerative Colitis
2023-10-15 22:37 ET
Astellas to Share New Data Across Hard-to-Treat Cancers During ESMO Congress 2023
2023-10-13 20:30 ET
Pfizer Amends U.S. Government Paxlovid Supply Agreement and Updates Full-Year 2023 Guidance
2023-10-13 13:00 ET
U.S. FDA Approves Pfizer’s VELSIPITY™ for Adults with Moderately to Severely Active Ulcerative Colitis (UC)
2023-10-12 10:45 ET
U.S. FDA Approves Pfizer’s BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
2023-10-05 20:30 ET
Pfizer Presents New Data at IDWeek 2023 Highlighting Advances in Prevention and Treatment of Certain Respiratory Illnesses and Other Infectious Diseases
2023-10-04 20:30 ET
Pfizer Declares Fourth-Quarter 2023 Dividend
2023-09-27 11:01 ET
Ginkgo Bioworks Announces Multi-Target RNA Discovery Collaboration with Pfizer
2023-09-22 19:16 ET
Pfizer Broadens Portfolio of Respiratory Vaccines Recommended by CDC Advisory Committee with ABRYSVO™ for RSV
2023-09-19 14:00 ET
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
2023-09-19 06:00 ET
European Commission Approves Pfizer’s LITFULO™ for Adolescents and Adults With Severe Alopecia Areata
2023-09-18 14:00 ET
Pfizer Invites Public to View and Listen to Webcast of October 31 Conference Call with Analysts
2023-09-12 23:30 ET
European Medicines Agency Validates Type II Variation for Astellas' XTANDI® (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
2023-09-12 14:00 ET
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
2023-09-05 14:00 ET
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
2023-08-30 14:00 ET
Pfizer Invites Public to View and Listen to Two Webcasts of Pfizer Discussions at Healthcare Conferences
2023-08-24 15:52 ET
European Commission Approves Pfizer’s ABRYSVO™ to Help Protect Infants through Maternal Immunization and Older Adults from RSV
2023-08-24 00:15 ET
Everest Medicines Announces Interim Results for First Half of 2023
2023-08-23 10:45 ET
FDA Grants Priority Review for XTANDI® in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
2023-08-21 21:31 ET
U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Infants Through Active Immunization of Pregnant Individuals 32-36 Weeks of Gestational Age
2023-08-14 18:08 ET
Pfizer’s ELREXFIO™ Receives U.S. FDA Accelerated Approval for Relapsed or Refractory Multiple Myeloma
2023-08-01 10:45 ET
Pfizer Reports Second-Quarter 2023 Results
2023-07-27 10:45 ET
Pfizer Announces Executive Leadership to Advance Oncology Research and Development Strategy
2023-07-21 19:02 ET
Pfizer Announces Post-Tornado Relief Plans for Rocky Mount Community and Manufacturing Facility
2023-07-19 21:22 ET
Pfizer Announces New England Journal of Medicine Publication on Group B Streptococcus (GBS) Maternal Vaccine Candidate
2023-07-18 11:00 ET
Flagship Pioneering and Pfizer Partner to Accelerate Development of Innovative Medicines Targeting Unmet Needs
2023-06-27 10:45 ET
FDA Accepts Pfizer’s Application for Hemophilia B Gene Therapy Fidanacogene Elaparvovec
2023-06-26 10:45 ET
Pfizer Provides Update on GLP-1-RA Clinical Development Program for Adults with Obesity and Type 2 Diabetes Mellitus
2023-06-23 21:51 ET
FDA Approves Pfizer’s LITFULO™ (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata
2023-06-22 10:45 ET
Pfizer Declares Third-Quarter 2023 Dividend
2023-06-20 22:34 ET
Pfizer’s TALZENNA® in Combination with XTANDI® Receives U.S. FDA Approval
2023-06-20 14:00 ET
Pfizer Invites Public to View and Listen to Webcast of August 1 Conference Call with Analysts
2023-06-06 14:00 ET
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
2023-06-01 14:00 ET
Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options
2023-05-31 21:49 ET
U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults
2023-05-30 10:45 ET
Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial
2023-05-25 21:00 ET
Astellas Highlights Continued Delivery of Strong Cancer Portfolio and Pipeline at 2023 ASCO Annual Meeting
2023-05-25 21:00 ET
Pfizer Presents Scientific Advancements from its Leading Oncology Portfolio at ASCO 2023 Annual Meeting
2023-05-25 15:21 ET
Pfizer’s PAXLOVID™ Receives FDA Approval for Adult Patients at High Risk of Progression to Severe COVID-19
2023-05-18 20:59 ET
FDA Advisory Committee Votes in Support of Approval for Pfizer’s Vaccine Candidate to Help Prevent RSV in Infants Through Maternal Immunization
2023-05-16 23:15 ET
Pfizer Prices $31,000,000,000 Debt Offering
2023-05-16 10:00 ET
IDEAYA Expands Clinical Trial Collaboration and Supply Agreements with Pfizer to Support Registrational Trial Evaluating Darovasertib and Crizotinib Combination in First-Line Metastatic Uveal Melanoma
2023-05-15 11:52 ET
 Pfizer Announces Proposed Notes Offering
2023-05-02 10:45 ET
Pfizer Reports First-Quarter 2023 Results
2023-04-29 14:45 ET
XTANDI® (enzalutamide) plus Leuprolide Reduced the Risk of Metastasis by 58% in Non-Metastatic Hormone-Sensitive Prostate Cancer versus Placebo plus Leuprolide
2023-04-27 19:42 ET
U.S. FDA Approves PREVNAR 20®, Pfizer’s 20-valent Pneumococcal Conjugate Vaccine for Infants and Children
2023-04-26 20:30 ET
Pfizer Declares Second-Quarter 2023 Dividend
2023-04-21 13:45 ET
AM Best Affirms Credit Ratings of Blue Whale Re Ltd.
2023-04-13 14:00 ET
Pfizer Invites Shareholders to Attend Virtual-Only 2023 Annual Meeting of Shareholders on April 27
2023-04-04 10:45 ET
FDA Accepts Pfizer’s Supplemental New Drug Applications for BRAFTOVI + MEKTOVI
2023-03-31 15:15 ET
COVID Remains A Global Threat – NanoViricides Set To Begin Clinical Trials For Pan-Coronavirus Drug To Help Defeat COVID Once And For All
2023-03-21 14:00 ET
Pfizer Invites Public to View and Listen to Webcast of May 2 Conference Call with Analysts
2023-03-20 13:45 ET
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats
2023-03-16 23:30 ET
Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer
2023-03-16 19:18 ET
FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer’s PAXLOVID™
2023-03-13 23:30 ET
Astellas Announces Phase 3 China ARCHES Study of XTANDI® Meets Primary Endpoint
2023-03-10 11:45 ET
Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval
2023-02-28 21:40 ET
Pfizer Receives Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adults
2023-02-27 15:00 ET
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
2023-02-23 07:00 ET
ViiV Healthcare Announces Positive Data Demonstrating Long-acting Injectable Cabenuva (cabotegravir, rilpivirine) is as Effective as Daily Oral Biktarvy (BIC/FTC/TAF) for the Treatment of HIV-1
2023-02-22 11:45 ET
Pfizer’s Elranatamab Receives FDA and EMA Filing Acceptance
2023-02-21 11:45 ET
U.S. FDA Accepts Biologics License Application for Pfizer’s Respiratory Syncytial Virus Maternal Vaccine Candidate for Priority Review
2023-02-16 15:00 ET
Pfizer Announces Positive TALZENNA® and XTANDI® Combination Data from Phase 3 TALAPRO-2 Study
2023-02-16 11:45 ET
Pfizer Announces The Lancet Neurology Has Published Phase 3 Data for Zavegepant for the Acute Treatment of Migraine in Adults
2023-02-10 17:09 ET
FDA Approves Pfizer's Supplemental New Drug Application for CIBINQO® (abrocitinib)
2023-02-09 15:00 ET
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
2023-01-31 11:45 ET
PFIZER REPORTS RECORD FULL-YEAR 2022 RESULTS AND PROVIDES FULL-YEAR 2023 FINANCIAL GUIDANCE
2023-01-23 13:00 ET
Telescope Presents 2022 Fiscal Year Highlights and Investor Update
2023-01-17 11:45 ET
Pfizer Expands ‘An Accord for a Healthier World’ Product Offering to Include Full Portfolio for Greater Benefit to 1.2 Billion People in 45 Lower-Income Countries
2023-01-06 11:45 ET
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children
2023-01-03 15:00 ET
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
2022-12-29 11:45 ET
Pfizer Announces Positive Top-Line Results from Phase 3 Study of Hemophilia B Gene Therapy Candidate
2022-12-28 11:45 ET
U.S. FDA Accepts for Review the Biologics License Application for Pfizer’s Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents
2022-12-22 00:00 ET
Everest Medicines' Licensing Partner Pfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis
2022-12-21 11:45 ET
Pfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis
2022-12-20 15:00 ET
Pfizer Invites Public to View and Listen to Webcast of January 31 Conference Call with Analysts
2022-12-15 12:00 ET
Circle Pharma Appoints Stephen Kelsey, MB ChB, MD, to its Board of Directors
2022-12-10 18:00 ET
Pfizer Presents Updated Favorable Elranatamab Data from Pivotal Phase 2 MagnetisMM-3 Trial
2022-12-09 16:15 ET
Pfizer Declares First-Quarter 2023 Dividend

SEC forms

Show financial reports only

SEC form 8
2025-02-04 08:11 ET
Pfizer reported for 2024 q4
SEC form 8
2025-02-04 08:11 ET
Pfizer published news for 2024 q4
SEC form 10
2024-11-04 16:06 ET
Pfizer reported for 2024 q3
SEC form 8
2024-10-29 08:06 ET
Pfizer published news for 2024 q3
SEC form 8
2024-10-29 08:06 ET
Pfizer published news for 2024 q3
SEC form 10
2024-08-05 00:00 ET
Pfizer published news for 2024 q2
SEC form 8
2024-07-30 08:04 ET
Pfizer reported for 2024 q2
SEC form 8
2024-07-30 08:04 ET
Pfizer published news for 2024 q2
SEC form 10
2024-05-08 00:00 ET
Pfizer published news for 2024 q1
SEC form 8
2024-05-01 08:11 ET
Pfizer reported for 2024 q1
SEC form 8
2024-05-01 08:11 ET
Pfizer published news for 2024 q1
SEC form 10
2024-02-22 00:00 ET
Pfizer published news for 2023 q4
SEC form 8
2024-01-30 00:00 ET
Pfizer published news for 2023 q4
SEC form 8
2024-01-30 00:00 ET
Pfizer reported for 2023 q4
SEC form 8
2023-12-14 00:00 ET
Pfizer published news for 2023 q3
SEC form 8
2023-12-14 00:00 ET
Pfizer published news for 2023 q3
SEC form 10
2023-11-08 00:00 ET
Pfizer published news for 2023 q3
SEC form 8
2023-10-31 08:04 ET
Pfizer reported for 2023 q3
SEC form 8
2023-10-13 00:00 ET
Pfizer published news for 2023 q3
SEC form 10
2023-08-09 00:00 ET
Pfizer published news for 2023 q2
SEC form 6
2023-08-01 08:09 ET
Pfizer reported for 2023 q2
SEC form 8
2023-08-01 00:00 ET
Pfizer published news for 2023 q2
SEC form 6
2023-07-27 16:11 ET
Pfizer published news for 2023 q2
SEC form 6
2023-06-20 14:51 ET
Pfizer published news for 2023 q1
SEC form 6
2023-06-20 14:45 ET
Pfizer published news for 2023 q1
SEC form 10
2023-05-10 00:00 ET
Pfizer published news for 2023 q1
SEC form 6
2023-05-02 08:05 ET
Pfizer reported for 2023 q1
SEC form 8
2023-05-02 00:00 ET
Pfizer published news for 2023 q1
SEC form 6
2023-05-01 09:39 ET
Pfizer published news for 2023 q1
SEC form 6
2023-03-13 08:29 ET
Pfizer published news for 2022 q4
SEC form 10
2023-02-23 14:12 ET
Pfizer reported for 2022 q4
SEC form 10
2023-02-23 00:00 ET
Pfizer published news for 2022 q4
SEC form 6
2023-02-21 16:17 ET
Pfizer published news for 2022 q4
SEC form 6
2023-01-31 08:11 ET
Pfizer published news for 2022 q4
SEC form 8
2023-01-31 00:00 ET
Pfizer published news for 2022 q4
SEC form 6
2022-12-13 16:19 ET
Pfizer published news for 2022 q3
SEC form 10
2022-11-09 16:05 ET
Pfizer reported for 2022 q3
SEC form 10
2022-11-09 00:00 ET
Pfizer reported for 2022 q3
SEC form 6
2022-11-01 08:11 ET
Pfizer published news for 2022 q3
SEC form 8
2022-11-01 00:00 ET
Pfizer published news for 2022 q3
SEC form 10
2022-08-10 16:26 ET
Pfizer reported for 2022 q2
SEC form 10
2022-08-10 00:00 ET
Pfizer reported for 2022 q2
SEC form 6
2022-07-28 08:09 ET
Pfizer published news for 2022 q2
SEC form 8
2022-07-28 00:00 ET
Pfizer published news for 2022 q2
SEC form 6
2022-06-09 14:13 ET
Pfizer published news for 2022 q1
SEC form 6
2022-06-09 14:09 ET
Pfizer published news for 2022 q1
SEC form 10
2022-05-11 16:19 ET
Pfizer reported for 2022 q1
SEC form 10
2022-05-11 00:00 ET
Pfizer reported for 2022 q1
SEC form 6
2022-05-10 07:08 ET
Pfizer published news for 2022 q1
SEC form 6
2022-05-09 13:19 ET
Pfizer published news for 2022 q1
SEC form 6
2022-05-03 08:08 ET
Pfizer published news for 2022 q1
SEC form 8
2022-05-03 00:00 ET
Pfizer published news for 2022 q1
SEC form 6
2022-05-02 16:36 ET
Pfizer published news for 2022 q1
SEC form 6
2022-04-20 16:41 ET
Pfizer published news for 2022 q1
SEC form 8
2022-04-20 00:00 ET
Pfizer published news for 2022 q1
SEC form 6
2022-04-12 16:24 ET
Pfizer published news for 2022 q1
SEC form 6
2022-03-29 16:31 ET
Pfizer published news for 2021 q4
SEC form 6
2022-03-28 12:31 ET
Pfizer published news for 2021 q4
SEC form 6
2022-03-17 09:53 ET
Pfizer published news for 2021 q4
SEC form 10
2022-02-24 14:25 ET
Pfizer published news for 2021 q4
SEC form 10
2022-02-24 00:00 ET
Pfizer published news for 2021 q4
SEC form 6
2022-02-08 08:53 ET
Pfizer published news for 2021 q4
SEC form 8
2022-02-08 00:00 ET
Pfizer published news for 2021 q4
SEC form 6
2022-01-10 09:15 ET
Pfizer published news for 2021 q4
SEC form 6
2021-12-15 16:18 ET
Pfizer published news for 2021 q3
SEC form 6
2021-11-19 16:15 ET
Pfizer published news for 2021 q3
SEC form 10
2021-11-12 06:06 ET
Pfizer published news for 2021 q3
SEC form 10
2021-11-12 00:00 ET
Pfizer published news for 2021 q3
SEC form 6
2021-11-02 08:25 ET
Pfizer published news for 2021 q3
SEC form 8
2021-11-02 00:00 ET
Pfizer published news for 2021 q3
SEC form 6
2021-09-02 16:08 ET
Pfizer published news for 2021 q2
SEC form 6
2021-08-18 16:06 ET
Pfizer published news for 2021 q2
SEC form 10
2021-08-12 16:01 ET
Pfizer published news for 2021 q2
SEC form 10
2021-08-12 00:00 ET
Pfizer published news for 2021 q2
SEC form 6
2021-07-28 08:04 ET
Pfizer published news for 2021 q2
SEC form 8
2021-07-28 00:00 ET
Pfizer published news for 2021 q2
SEC form 6
2021-07-09 16:38 ET
Pfizer published news for 2021 q2
SEC form 6
2021-06-07 14:47 ET
Pfizer published news for 2021 q1
SEC form 6
2021-06-07 14:45 ET
Pfizer published news for 2021 q1
SEC form 6
2021-06-07 14:44 ET
Pfizer published news for 2021 q1
SEC form 10
2021-05-13 11:32 ET
Pfizer published news for 2021 q1
SEC form 10
2021-05-13 00:00 ET
Pfizer published news for 2021 q1
SEC form 6
2021-05-04 08:15 ET
Pfizer published news for 2021 q1
SEC form 8
2021-05-04 00:00 ET
Pfizer published news for 2021 q1
SEC form 6
2021-04-26 09:30 ET
Pfizer published news for 2021 q1
SEC form 6
2021-03-12 09:32 ET
Pfizer published news for 2020 q4
SEC form 10
2021-02-25 13:59 ET
Pfizer published news for 2020 q4
SEC form 6
2021-02-02 08:34 ET
Pfizer published news for 2020 q4
SEC form 6
2021-01-12 10:59 ET
Pfizer published news for 2020 q4
SEC form 6
2020-12-14 17:01 ET
Pfizer published news for 2020 q3
SEC form 6
2020-11-19 18:38 ET
Pfizer published news for 2020 q3
SEC form 6
2020-11-18 16:32 ET
Pfizer published news for 2020 q3
SEC form 6
2020-11-16 16:35 ET
Pfizer published news for 2020 q3
SEC form 6
2020-11-13 17:05 ET
Pfizer published news for 2020 q3
SEC form 10
2020-11-05 16:57 ET
Pfizer published news for 2020 q3
SEC form 6
2020-11-05 16:42 ET
Pfizer published news for 2020 q3
SEC form 6
2020-10-30 17:10 ET
Pfizer published news for 2020 q3
SEC form 6
2020-10-27 08:11 ET
Pfizer published news for 2020 q3